23 November, 2015
3SBio Inc. announced on November 20, 2015 that it has entered into a number of agreements pursuant to which it will acquire Shanghai CP Guojian Pharmaceutical for an aggregate consideration of approximately US$214 million, enabling it to significantly expand its portfolio of biopharmaceutical products.
Skadden represented 3SBio on the transaction, which follows the firm's representation of 3SBio on its highly successful June 2015 Hong Kong IPO that raised approximately US$818 million. The Skadden team included partners Peter Huang and Chris Betts, counsel Andre Zhu and associates Paul Mok and Ning Dong.
